Research ExplorerPublicationsNovel cryoballoon ablation system for pulmonary vein isolati...

Novel cryoballoon ablation system for pulmonary vein isolation: multicenter assessment of efficacy and safety-ANTARCTICA study

Standard

Novel cryoballoon ablation system for pulmonary vein isolation: multicenter assessment of efficacy and safety-ANTARCTICA study. / Heeger, Christian-H; Pott, Alexander; Sohns, Christian; Riesinger, Lisa; Sommer, Philipp; Gasperetti, Alessio; Tondo, Claudio; Fassini, Gaetano; Moser, Fabian; Lucas, Philipp; Weinmann, Karolina; Bohnen, Jan-Eric; Dahme, Tillman; Rillig, Andreas; Kuck, Karl-Heinz; Wakili, Reza; Metzner, Andreas; Tilz, Roland R.

In: EUROPACE, Vol. 24, No. 12, 09.12.2022, p. 1917-1925.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Heeger, C-H, Pott, A, Sohns, C, Riesinger, L, Sommer, P, Gasperetti, A, Tondo, C, Fassini, G, Moser, F, Lucas, P, Weinmann, K, Bohnen, J-E, Dahme, T, Rillig, A, Kuck, K-H, Wakili, R, Metzner, A & Tilz, RR 2022, 'Novel cryoballoon ablation system for pulmonary vein isolation: multicenter assessment of efficacy and safety-ANTARCTICA study', EUROPACE, vol. 24, no. 12, pp. 1917-1925. https://doi.org/10.1093/europace/euac148

APA

Heeger, C-H., Pott, A., Sohns, C., Riesinger, L., Sommer, P., Gasperetti, A., Tondo, C., Fassini, G., Moser, F., Lucas, P., Weinmann, K., Bohnen, J-E., Dahme, T., Rillig, A., Kuck, K-H., Wakili, R., Metzner, A., & Tilz, R. R. (2022). Novel cryoballoon ablation system for pulmonary vein isolation: multicenter assessment of efficacy and safety-ANTARCTICA study. EUROPACE, 24(12), 1917-1925. https://doi.org/10.1093/europace/euac148

Vancouver

Heeger C-H, Pott A, Sohns C, Riesinger L, Sommer P, Gasperetti A et al. Novel cryoballoon ablation system for pulmonary vein isolation: multicenter assessment of efficacy and safety-ANTARCTICA study. EUROPACE. 2022 Dec 9;24(12):1917-1925. https://doi.org/10.1093/europace/euac148

Bibtex

@article{c81b78a2d57a4f3786dee714f4f4f0de,
title = "Novel cryoballoon ablation system for pulmonary vein isolation: multicenter assessment of efficacy and safety-ANTARCTICA study",
abstract = "AIMS: Pulmonary vein isolation (PVI) either by balloon devices or radiofrequency forms the cornerstone of invasive atrial fibrillation (AF) treatment. Although equally effective cryoballoon (CB)-based PVI offers shorter procedure duration and a better safety profile. Beside the worldwide established Arctic Front Advance system, a novel CB device, POLARx, was recently introduced. This CB incorporates unique features, which may translate into improved efficacy and safety. However, multicentre assessment of periprocedural efficacy and safety is lacking up to date.METHODS AND RESULTS: A total of 317 patients with paroxysmal or persistent AF were included and underwent POLARx CB-based PVI in 6 centres from Germany and Italy. Acute efficacy and safety were assessed in this prospective multicenter observational study. In 317 patients [mean age: 64 ± 12 years, 209 of 317 (66%) paroxysmal AF], a total of 1256 pulmonary veins (PVs) were identified and 1252 (99,7%) PVs were successfully isolated utilizing mainly the short tip POLARx CB (82%). The mean minimal CB temperature was -57.9 ± 7°C. Real-time PVI was registered in 72% of PVs. The rate of serious adverse events was 6.0% which was significantly reduced after a learning curve of 25 cases (9.3% vs. 3.0%, P = 0.018). The rate of recurrence-free survival after mean follow-up of 226 ± 115 days including a 90-day blanking period was 86.1%.CONCLUSION: In this large multicentre assessment, the novel POLARx CB shows a promising efficacy and safety profile after a short learning curve.",
keywords = "Humans, Middle Aged, Aged, Pulmonary Veins/surgery, Cryosurgery, Catheter Ablation/methods, Prospective Studies, Treatment Outcome, Atrial Fibrillation/diagnosis",
author = "Christian-H Heeger and Alexander Pott and Christian Sohns and Lisa Riesinger and Philipp Sommer and Alessio Gasperetti and Claudio Tondo and Gaetano Fassini and Fabian Moser and Philipp Lucas and Karolina Weinmann and Jan-Eric Bohnen and Tillman Dahme and Andreas Rillig and Karl-Heinz Kuck and Reza Wakili and Andreas Metzner and Tilz, {Roland R}",
note = "{\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.",
year = "2022",
month = dec,
day = "9",
doi = "10.1093/europace/euac148",
language = "English",
volume = "24",
pages = "1917--1925",
journal = "EUROPACE",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "12",

}

RIS

TY - JOUR

T1 - Novel cryoballoon ablation system for pulmonary vein isolation: multicenter assessment of efficacy and safety-ANTARCTICA study

AU - Heeger, Christian-H

AU - Pott, Alexander

AU - Sohns, Christian

AU - Riesinger, Lisa

AU - Sommer, Philipp

AU - Gasperetti, Alessio

AU - Tondo, Claudio

AU - Fassini, Gaetano

AU - Moser, Fabian

AU - Lucas, Philipp

AU - Weinmann, Karolina

AU - Bohnen, Jan-Eric

AU - Dahme, Tillman

AU - Rillig, Andreas

AU - Kuck, Karl-Heinz

AU - Wakili, Reza

AU - Metzner, Andreas

AU - Tilz, Roland R

N1 - © The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

PY - 2022/12/9

Y1 - 2022/12/9

N2 - AIMS: Pulmonary vein isolation (PVI) either by balloon devices or radiofrequency forms the cornerstone of invasive atrial fibrillation (AF) treatment. Although equally effective cryoballoon (CB)-based PVI offers shorter procedure duration and a better safety profile. Beside the worldwide established Arctic Front Advance system, a novel CB device, POLARx, was recently introduced. This CB incorporates unique features, which may translate into improved efficacy and safety. However, multicentre assessment of periprocedural efficacy and safety is lacking up to date.METHODS AND RESULTS: A total of 317 patients with paroxysmal or persistent AF were included and underwent POLARx CB-based PVI in 6 centres from Germany and Italy. Acute efficacy and safety were assessed in this prospective multicenter observational study. In 317 patients [mean age: 64 ± 12 years, 209 of 317 (66%) paroxysmal AF], a total of 1256 pulmonary veins (PVs) were identified and 1252 (99,7%) PVs were successfully isolated utilizing mainly the short tip POLARx CB (82%). The mean minimal CB temperature was -57.9 ± 7°C. Real-time PVI was registered in 72% of PVs. The rate of serious adverse events was 6.0% which was significantly reduced after a learning curve of 25 cases (9.3% vs. 3.0%, P = 0.018). The rate of recurrence-free survival after mean follow-up of 226 ± 115 days including a 90-day blanking period was 86.1%.CONCLUSION: In this large multicentre assessment, the novel POLARx CB shows a promising efficacy and safety profile after a short learning curve.

AB - AIMS: Pulmonary vein isolation (PVI) either by balloon devices or radiofrequency forms the cornerstone of invasive atrial fibrillation (AF) treatment. Although equally effective cryoballoon (CB)-based PVI offers shorter procedure duration and a better safety profile. Beside the worldwide established Arctic Front Advance system, a novel CB device, POLARx, was recently introduced. This CB incorporates unique features, which may translate into improved efficacy and safety. However, multicentre assessment of periprocedural efficacy and safety is lacking up to date.METHODS AND RESULTS: A total of 317 patients with paroxysmal or persistent AF were included and underwent POLARx CB-based PVI in 6 centres from Germany and Italy. Acute efficacy and safety were assessed in this prospective multicenter observational study. In 317 patients [mean age: 64 ± 12 years, 209 of 317 (66%) paroxysmal AF], a total of 1256 pulmonary veins (PVs) were identified and 1252 (99,7%) PVs were successfully isolated utilizing mainly the short tip POLARx CB (82%). The mean minimal CB temperature was -57.9 ± 7°C. Real-time PVI was registered in 72% of PVs. The rate of serious adverse events was 6.0% which was significantly reduced after a learning curve of 25 cases (9.3% vs. 3.0%, P = 0.018). The rate of recurrence-free survival after mean follow-up of 226 ± 115 days including a 90-day blanking period was 86.1%.CONCLUSION: In this large multicentre assessment, the novel POLARx CB shows a promising efficacy and safety profile after a short learning curve.

KW - Humans

KW - Middle Aged

KW - Aged

KW - Pulmonary Veins/surgery

KW - Cryosurgery

KW - Catheter Ablation/methods

KW - Prospective Studies

KW - Treatment Outcome

KW - Atrial Fibrillation/diagnosis

U2 - 10.1093/europace/euac148

DO - 10.1093/europace/euac148

M3 - SCORING: Journal article

C2 - 36026521

VL - 24

SP - 1917

EP - 1925

JO - EUROPACE

JF - EUROPACE

SN - 1099-5129

IS - 12

ER -